ARK Genomic Revolution ETF
ARKG
239 hedge funds and large institutions have $854M invested in ARK Genomic Revolution ETF in 2025 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 65 increasing their positions, 56 reducing their positions, and 44 closing their positions.
39% more capital invested
Capital invested by funds: $614M → $854M (+$240M)
18% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 44
17.59% more ownership
Funds ownership: 54.79% → 72.38% (+18%)
16% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 56
3% more funds holding
Funds holding: 233 → 239 (+6)
70% less call options, than puts
Call options by funds: $103M | Put options by funds: $342M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$39.4M |
| 2 |
JP Morgan Chase
New York
|
+$36.2M |
| 3 |
Morgan Stanley
New York
|
+$35.8M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$35M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$29.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KF
Krilogy Financial
St. Louis,
Missouri
|
-$5.81M |
| 2 |
Goldman Sachs
New York
|
-$4.67M |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
-$4.56M |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$3.31M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$3.28M |
ARKG Hedge Fund Activity: Q4 2025 in Review
239 of the 8,265 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2025, worth a combined $854M — up 39% from $614M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new ARKG positions and 44 closed out — a net gain of 8 holders — while 65 added to existing stakes and 56 trimmed.
The largest buyer was Citigroup, adding an estimated $39.4M. The largest seller was Krilogy Financial, exiting entirely with an estimated $5.81M sold.
- 239 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2025, up from 233 in Q3 2025.
- Funds reported $854M of ARK Genomic Revolution ETF stock for Q4 2025, up 39% quarter-over-quarter.
- 52 funds opened new ARK Genomic Revolution ETF positions in Q4 2025 and 44 closed out, a net change of +8 holders.
- The largest ARK Genomic Revolution ETF buyer in Q4 2025 was Citigroup, an estimated $39.4M added.
- The largest ARK Genomic Revolution ETF seller in Q4 2025 was Krilogy Financial, an estimated $5.81M sold.
Based on aggregated 13F filings for Q4 2025.